What is Mixed Connective Tissue Disease?
Mixed Connective Tissue Disease (MCTD) is a distinct systemic autoimmune disorder characterised by overlapping clinical features of three major connective tissue diseases — Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (Scleroderma), and Polymyositis/Dermatomyositis — occurring simultaneously in the same patient, combined with the presence of high-titre anti-U1-RNP antibodies.
Described by Sharp and colleagues in 1972, MCTD was originally proposed as a distinct disease with a benign prognosis. We now understand that it has its own characteristic organ manifestations, natural history, and complications — most significantly, Pulmonary Arterial Hypertension (PAH), which is the leading cause of mortality in MCTD.
Puffy, swollen hands — a very characteristic and early finding in Mixed Connective Tissue Disease.
Clinical Features
The overlapping features from the three component diseases create a unique clinical picture:
- From SLE: Joint pain, skin rashes, serositis (pleuritis/pericarditis), haematological abnormalities.
- From Scleroderma: Raynaud's phenomenon (often the first and most prominent symptom), oesophageal dysmotility, sclerodactyly, puffy hands (a very characteristic feature of MCTD).
- From Polymyositis: Proximal muscle weakness, elevated muscle enzymes (CK, aldolase).
- Pulmonary Arterial Hypertension: Occurs in 10-45% of MCTD patients — the most serious and potentially fatal complication.
- Inflammatory Arthritis: Often polyarticular, resembling RA, and can be erosive.
- Trigeminal Neuralgia: Facial pain from trigeminal nerve involvement — a distinctive feature of MCTD.
Raynaud's phenomenon with classic triphasic colour changes is the most common initial symptom of MCTD.
🔑 The Diagnostic Key: Anti-U1-RNP Antibodies
The presence of high-titre anti-U1-RNP antibodies is the defining serological feature of MCTD. All patients with MCTD have a positive ANA (typically in a speckled pattern) and high-titre anti-U1-RNP. The absence of anti-Sm, anti-dsDNA, anti-Ro, and anti-La antibodies (which would suggest SLE) helps confirm the MCTD diagnosis.
Dr. Prateek's Approach to MCTD
MCTD requires a Rheumatologist who is intimately familiar with all three component diseases and can identify which disease domain is currently predominating and needs the most aggressive treatment. Dr. Prateek Deo provides this nuanced, multi-domain management.
PAH Screening
Annual echocardiography screening for Pulmonary Arterial Hypertension — the most dangerous complication of MCTD — with early referral for right heart catheterization when needed.
Domain-Specific Therapy
We treat each active disease domain appropriately — immunosuppression for inflammatory features, vasodilators for Raynaud's and PAH, and physiotherapy for myositis.
Hydroxychloroquine Backbone
Hydroxychloroquine is maintained as a background therapy in all MCTD patients for its disease-modifying and cardioprotective effects.
Serial Reassessment
MCTD can evolve over time — some patients "differentiate" into pure SLE or SSc. We monitor for this evolution with regular clinical and serological reassessment.